Daridorexant Effective for Insomnia in Phase 3 Trial

The Idorsia drug candidate demonstrated minimal serious treatment-emergent adverse events, with no rebound insomnia or withdrawal symptoms upon discontinuation.

from Front page feed https://ift.tt/2Yaipjv